Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.

Wright TD, Raybuck C, Bhatt A, Monlish D, Chakrabarty S, Wendekier K, Gartland N, Gupta M, Burow ME, Flaherty PT, Cavanaugh JE.

J Cell Biochem. 2019 Aug 28. doi: 10.1002/jcb.29350. [Epub ahead of print]

PMID:
31464004
2.

Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer.

Bhatt AB, Gupta M, Hoang VT, Chakrabarty S, Wright TD, Elliot S, Chopra IK, Monlish D, Anna K, Burow ME, Cavanaugh JE, Flaherty PT.

Front Oncol. 2019 Jul 30;9:672. doi: 10.3389/fonc.2019.00672. eCollection 2019.

3.

Implementation of an Automated Pediatric Malnutrition Screen Using Anthropometric Measurements in the Electronic Health Record.

Phillips CA, Bailer J, Foster E, Dogan P, Flaherty P, Baniewicz D, Smith E, Reilly A, Freedman J.

J Acad Nutr Diet. 2019 Aug;119(8):1243-1249. doi: 10.1016/j.jand.2018.07.014. Epub 2018 Oct 5. No abstract available.

PMID:
30297315
4.

Same versus next day discharge after elective transradial PCI: The RAdial SAme Day DischArge after PCI trial. (The RASADDA-PCI trial).

Rodriguez-Araujo G, Cilingiroglu M, Mego D, Hakeem A, Lendel V, Cawich I, Paixao A, Marmagkiolis K, Flaherty P, Rollefson W.

Cardiovasc Revasc Med. 2018 Sep;19(6S):7-11. doi: 10.1016/j.carrev.2018.05.020. Epub 2018 Jun 2.

PMID:
29937383
5.

Structure activity relationships of anthranilic acid-based compounds on cellular and in vivo mitogen activated protein kinase-5 signaling pathways.

Chakrabarty S, Monlish DA, Gupta M, Wright TD, Hoang VT, Fedak M, Chopra I, Flaherty PT, Madura J, Mannepelli S, Burow ME, Cavanaugh JE.

Bioorg Med Chem Lett. 2018 Jul 15;28(13):2294-2301. doi: 10.1016/j.bmcl.2018.05.029. Epub 2018 May 20. No abstract available.

PMID:
29803729
6.

Conditional genetic screen in Physcomitrella patens reveals a novel microtubule depolymerizing-end-tracking protein.

Ding X, Pervere LM, Bascom C Jr, Bibeau JP, Khurana S, Butt AM, Orr RG, Flaherty PJ, Bezanilla M, Vidali L.

PLoS Genet. 2018 May 10;14(5):e1007221. doi: 10.1371/journal.pgen.1007221. eCollection 2018 May.

7.

Erratum for Mor et al., "Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids".

Mor V, Rella A, Farnoud AM, Singh A, Munshi M, Bryan A, Naseem S, Konopka JB, Ojima I, Bullesbach E, Ashbaugh A, Linke MJ, Cushion M, Collins M, Ananthula HK, Sallans L, Desai PB, Wiederhold NP, Fothergill AW, Kirkpatrick WR, Patterson T, Wong LH, Sinha S, Giaever G, Nislow C, Flaherty P, Pan X, Cesar GV, de Melo Tavares P, Frases S, Miranda K, Rodrigues ML, Luberto C, Nimrichter L, Del Poeta M.

MBio. 2018 Mar 13;9(2). pii: e00188-18. doi: 10.1128/mBio.00188-18. No abstract available.

8.

N-Acetyl-l-Cysteine Protects Astrocytes against Proteotoxicity without Recourse to Glutathione.

Gleixner AM, Hutchison DF, Sannino S, Bhatia TN, Leak LC, Flaherty PT, Wipf P, Brodsky JL, Leak RK.

Mol Pharmacol. 2017 Nov;92(5):564-575. doi: 10.1124/mol.117.109926. Epub 2017 Aug 22.

9.

Comparative functional genomic screens of three yeast deletion collections reveal unexpected effects of genotype in response to diverse stress.

Acton E, Lee AH, Zhao PJ, Flibotte S, Neira M, Sinha S, Chiang J, Flaherty P, Nislow C, Giaever G.

Open Biol. 2017 Jun;7(6). pii: 160330. doi: 10.1098/rsob.160330.

10.

Oncogenic signaling of MEK5-ERK5.

Hoang VT, Yan TJ, Cavanaugh JE, Flaherty PT, Beckman BS, Burow ME.

Cancer Lett. 2017 Apr 28;392:51-59. doi: 10.1016/j.canlet.2017.01.034. Epub 2017 Jan 30. Review.

11.

Variational inference for rare variant detection in deep, heterogeneous next-generation sequencing data.

Zhang F, Flaherty P.

BMC Bioinformatics. 2017 Jan 19;18(1):45. doi: 10.1186/s12859-016-1451-5.

12.

Reverse Chemical Genetics: Comprehensive Fitness Profiling Reveals the Spectrum of Drug Target Interactions.

Wong LH, Sinha S, Bergeron JR, Mellor JC, Giaever G, Flaherty P, Nislow C.

PLoS Genet. 2016 Sep 2;12(9):e1006275. doi: 10.1371/journal.pgen.1006275. eCollection 2016 Sep.

13.

Canadian Stroke Best Practice Recommendations: Managing transitions of care following Stroke, Guidelines Update 2016.

Cameron JI, O'Connell C, Foley N, Salter K, Booth R, Boyle R, Cheung D, Cooper N, Corriveau H, Dowlatshahi D, Dulude A, Flaherty P, Glasser E, Gubitz G, Hebert D, Holzmann J, Hurteau P, Lamy E, LeClaire S, McMillan T, Murray J, Scarfone D, Smith EE, Shum V, Taylor K, Taylor T, Yanchula C, Teasell R, Lindsay P; Heart and Stroke Foundation Canadian Stroke Best Practice Committees.

Int J Stroke. 2016 Oct;11(7):807-22. doi: 10.1177/1747493016660102. Epub 2016 Jul 21.

PMID:
27443991
14.

GEMINI: a computationally-efficient search engine for large gene expression datasets.

DeFreitas T, Saddiki H, Flaherty P.

BMC Bioinformatics. 2016 Feb 24;17:102. doi: 10.1186/s12859-016-0934-8.

15.

Robust Optimization of Biological Protocols.

Flaherty P, Davis RW.

Technometrics. 2015;57(2):234-244. Epub 2015 Jul 13.

16.

Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target.

Bisht S, Nolting J, Schütte U, Haarmann J, Jain P, Shah D, Brossart P, Flaherty P, Feldmann G.

Transl Oncol. 2015 Aug;8(4):295-307. doi: 10.1016/j.tranon.2015.06.002.

17.

Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids.

Mor V, Rella A, Farnoud AM, Singh A, Munshi M, Bryan A, Naseem S, Konopka JB, Ojima I, Bullesbach E, Ashbaugh A, Linke MJ, Cushion M, Collins M, Ananthula HK, Sallans L, Desai PB, Wiederhold NP, Fothergill AW, Kirkpatrick WR, Patterson T, Wong LH, Sinha S, Giaever G, Nislow C, Flaherty P, Pan X, Cesar GV, de Melo Tavares P, Frases S, Miranda K, Rodrigues ML, Luberto C, Nimrichter L, Del Poeta M.

MBio. 2015 Jun 23;6(3):e00647. doi: 10.1128/mBio.00647-15. Erratum in: MBio. 2018 Mar 13;9(2):.

18.

RVD2: an ultra-sensitive variant detection model for low-depth heterogeneous next-generation sequencing data.

He Y, Zhang F, Flaherty P.

Bioinformatics. 2015 Sep 1;31(17):2785-93. doi: 10.1093/bioinformatics/btv275. Epub 2015 Apr 29.

19.

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM.

J Clin Oncol. 2015 Jun 10;33(17):1895-901. doi: 10.1200/JCO.2014.57.0085. Epub 2015 Apr 6.

20.

The unlikely presence of deep vein thrombosis in a patient with low pretest probability and a negative D-dimer: a case report.

Ramsey SC, Flaherty PM.

J Emerg Med. 2015 Jun;48(6):671-4. doi: 10.1016/j.jemermed.2014.12.055. Epub 2015 Apr 3.

PMID:
25843927
21.

Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.

Nadauld LD, Garcia S, Natsoulis G, Bell JM, Miotke L, Hopmans ES, Xu H, Pai RK, Palm C, Regan JF, Chen H, Flaherty P, Ootani A, Zhang NR, Ford JM, Kuo CJ, Ji HP.

Genome Biol. 2014 Aug 27;15(8):428. doi: 10.1186/s13059-014-0428-9.

22.

GLAD: a mixed-membership model for heterogeneous tumor subtype classification.

Saddiki H, McAuliffe J, Flaherty P.

Bioinformatics. 2015 Jan 15;31(2):225-32. doi: 10.1093/bioinformatics/btu618. Epub 2014 Sep 29.

23.

Prediction of multiple infections after severe burn trauma: a prospective cohort study.

Yan S, Tsurumi A, Que YA, Ryan CM, Bandyopadhaya A, Morgan AA, Flaherty PJ, Tompkins RG, Rahme LG.

Ann Surg. 2015 Apr;261(4):781-92. doi: 10.1097/SLA.0000000000000759.

24.

Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis.

Lee H, Flaherty P, Ji HP.

BMC Med Genomics. 2013 Dec 5;6:54. doi: 10.1186/1755-8794-6-54.

25.

RVD: a command-line program for ultrasensitive rare single nucleotide variant detection using targeted next-generation DNA resequencing.

Cushing A, Flaherty P, Hopmans E, Bell JM, Ji HP.

BMC Res Notes. 2013 May 23;6:206. doi: 10.1186/1756-0500-6-206.

26.

The effect of the steroid sulfatase inhibitor (p-O-sulfamoyl)-tetradecanoyl tyramine (DU-14) on learning and memory in rats with selective lesion of septal-hippocampal cholinergic tract.

Babalola PA, Fitz NF, Gibbs RB, Flaherty PT, Li PK, Johnson DA.

Neurobiol Learn Mem. 2012 Oct;98(3):303-10. doi: 10.1016/j.nlm.2012.09.003. Epub 2012 Sep 26.

27.

Don't get bugged: practical strategies for managing bedbug infestation in psychiatric rehabilitation programs.

Zipple AM, Batscha CL, Flaherty P, Reynolds JL.

J Psychosoc Nurs Ment Health Serv. 2012 Jul;50(7):22-6. doi: 10.3928/02793695-20120605-02. Epub 2012 Jun 15.

PMID:
22694784
28.

Identification of HIV inhibitors guided by free energy perturbation calculations.

Acevedo O, Ambrose Z, Flaherty PT, Aamer H, Jain P, Sambasivarao SV.

Curr Pharm Des. 2012;18(9):1199-216. Review.

29.

Scale-up of mammalian cell culture using a new multilayered flask.

Abraham EJ, Slater KA, Sanyal S, Linehan K, Flaherty PM, Qian S.

J Vis Exp. 2011 Dec 5;(58). pii: 3418. doi: 10.3791/3418.

30.

Ultrasensitive detection of rare mutations using next-generation targeted resequencing.

Flaherty P, Natsoulis G, Muralidharan O, Winters M, Buenrostro J, Bell J, Brown S, Holodniy M, Zhang N, Ji HP.

Nucleic Acids Res. 2012 Jan;40(1):e2. doi: 10.1093/nar/gkr861. Epub 2011 Oct 19.

31.

Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket.

Yuan J, Simpson RD, Zhao W, Tice CM, Xu Z, Cacatian S, Jia L, Flaherty PT, Guo J, Ishchenko A, Wu Z, McKeever BM, Scott BB, Bukhtiyarov Y, Berbaum J, Panemangalore R, Bentley R, Doe CP, Harrison RK, McGeehan GM, Singh SB, Dillard LW, Baldwin JJ, Claremon DA.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4836-43. doi: 10.1016/j.bmcl.2011.06.043. Epub 2011 Jun 17.

PMID:
21741239
32.

Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25.

Jain P, Flaherty PT, Yi S, Chopra I, Bleasdell G, Lipay J, Ferandin Y, Meijer L, Madura JD.

Bioorg Med Chem. 2011 Jan 1;19(1):359-73. doi: 10.1016/j.bmc.2010.11.022. Epub 2010 Dec 6.

PMID:
21144757
33.

Structure-activity relationships of benzimidazole-based selective inhibitors of the mitogen activated kinase-5 signaling pathway.

Flaherty PT, Chopra I, Jain P, Monlish D, Cavanaugh J.

Bioorg Med Chem. 2010 Nov 15;18(22):8054-60. doi: 10.1016/j.bmc.2010.09.017. Epub 2010 Oct 19.

PMID:
20965737
34.

Identification of benzimidazole-based inhibitors of the mitogen activated kinase-5 signaling pathway.

Flaherty PT, Chopra I, Jain P, Yi S, Allen E, Cavanaugh J.

Bioorg Med Chem Lett. 2010 May 1;20(9):2892-6. doi: 10.1016/j.bmcl.2010.03.033. Epub 2010 Mar 10.

PMID:
20382528
35.

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD.

Cancer Res. 2010 Jan 15;70(2):512-9. doi: 10.1158/0008-5472.CAN-09-1851. Epub 2010 Jan 12.

36.

A poly-N-acetyl glucosamine hemostatic dressing for femoral artery access site hemostasis after percutaneous coronary intervention: a pilot study.

Mego D, Thomas M, Stewart J, Rollefson W, Flaherty P, Murphy B, Ribeiro P.

J Invasive Cardiol. 2010 Jan;22(1):35-9.

PMID:
20048398
37.

Optimization of orally bioavailable alkyl amine renin inhibitors.

Xu Z, Cacatian S, Yuan J, Simpson RD, Jia L, Zhao W, Tice CM, Flaherty PT, Guo J, Ishchenko A, Singh SB, Wu Z, McKeever BM, Scott BB, Bukhtiyarov Y, Berbaum J, Mason J, Panemangalore R, Cappiello MG, Bentley R, Doe CP, Harrison RK, McGeehan GM, Dillard LW, Baldwin JJ, Claremon DA.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):694-9. doi: 10.1016/j.bmcl.2009.11.066. Epub 2009 Dec 1.

PMID:
19959358
38.

An in vitro FluoroBlok tumor invasion assay.

Partridge J, Flaherty P.

J Vis Exp. 2009 Jul 20;(29). pii: 1475. doi: 10.3791/1475.

39.

Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.

Tice CM, Xu Z, Yuan J, Simpson RD, Cacatian ST, Flaherty PT, Zhao W, Guo J, Ishchenko A, Singh SB, Wu Z, Scott BB, Bukhtiyarov Y, Berbaum J, Mason J, Panemangalore R, Cappiello MG, Müller D, Harrison RK, McGeehan GM, Dillard LW, Baldwin JJ, Claremon DA.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3541-5. doi: 10.1016/j.bmcl.2009.04.140. Epub 2009 May 5.

PMID:
19457666
40.

A dual receptor crosstalk model of G-protein-coupled signal transduction.

Flaherty P, Radhakrishnan ML, Dinh T, Rebres RA, Roach TI, Jordan MI, Arkin AP.

PLoS Comput Biol. 2008 Sep 26;4(9):e1000185. doi: 10.1371/journal.pcbi.1000185.

41.

Horner syndrome due to carotid dissection.

Flaherty PM, Flynn JM.

J Emerg Med. 2011 Jul;41(1):43-6. doi: 10.1016/j.jemermed.2008.01.017. Epub 2008 Sep 14. Review.

PMID:
18790590
42.

1-Isopropyl-4-nitro-6-meth-oxy-1H-benzimidazole.

Moore MD, Jain P, Flaherty PT, Wildfong PL.

Acta Crystallogr Sect E Struct Rep Online. 2008 Jun 25;64(Pt 7):o1336-7. doi: 10.1107/S160053680801859X.

43.

Genome-wide requirements for resistance to functionally distinct DNA-damaging agents.

Lee W, St Onge RP, Proctor M, Flaherty P, Jordan MI, Arkin AP, Davis RW, Nislow C, Giaever G.

PLoS Genet. 2005 Aug;1(2):e24. Epub 2005 Aug 19.

44.

Plasmodium chabaudi adami: use of the B-cell-deficient mouse to define possible mechanisms modulating parasitemia of chronic malaria.

Weidanz WP, Batchelder JM, Flaherty P, LaFleur G, Wong C, van der Heyde HC.

Exp Parasitol. 2005 Oct;111(2):97-104.

PMID:
16087175
45.

A latent variable model for chemogenomic profiling.

Flaherty P, Giaever G, Kumm J, Jordan MI, Arkin AP.

Bioinformatics. 2005 Aug 1;21(15):3286-93. Epub 2005 May 26.

PMID:
15919724
46.

Synthesis and anti-tubulin activity of a 3'-(4-azidophenyl)-3'-dephenylpaclitaxel photoaffinity probe.

Spletstoser JT, Flaherty PT, Himes RH, Georg GI.

J Med Chem. 2004 Dec 16;47(26):6459-65.

PMID:
15588080
47.
48.

CD28 costimulation is required for the expression of T-cell-dependent cell-mediated immunity against blood-stage Plasmodium chabaudi malaria parasites.

Rummel T, Batchelder J, Flaherty P, LaFleur G, Nanavati P, Burns JM, Weidanz WP.

Infect Immun. 2004 Oct;72(10):5768-74.

Supplemental Content

Loading ...
Support Center